World Hepatitis Day 2024

Today marks the global public health day officially mandated by the World Health Organization, celebrated annually on 28 July. And this year, it is more important than ever.

 

1.3 million people lose their lives to hepatitis each year – because they weren’t tested, or didn’t have access to treatment, or were never vaccinated. 

And new data from the World Health Organization shows the number of deaths is rising. 

Hepatitis is now the world’s deadliest virus, after COVID-19, and more than 300 million people are living with it. With only six years left to meet the global goal of eliminating hepatitis by 2030, we are moving backwards. 

 

Taking action.

For World Hepatitis Day 2024, WHA, our partners, allies, and our 337 members in 102 countries are calling for action to end this entirely preventable disease.

We have the tools we need to eliminate hepatitis by 2030 – but progress is still too slow. Resources are not being mobilised; stigma and discrimination are not being addressed; and despite commitments made by governments and institutions, millions are being left behind.

 

There is no time to waste.

World Hepatitis Day 2024, is providing a platform for this message, and making sure it is heard by those with the power to make real change happen. It will amplify the voices of people living with hepatitis demanding testing, treatment, vaccinations and the end of stigma. It will make it clear there is no time to waste, and that leaders, politicians, doctors and communities must act now.

People living with hepatitis are still not being heard or getting the resources they need, despite the global scale of the problem.

This World Hepatitis Day, it’s time for action.

 

Visit worldhepatitisday.org to pledge your support, download free resources, and take action!

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close